Want to see CNSP full AI Analyst Report?
Top Page
CNS Pharmaceuticals
(NASDAQ:CNSP)
Select Model
Select Model
Rating:49Neutral
Price Target:
$5.00
▼(-16.81% Downside)
Action:Reiterated
Date:07/03/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and persistent cash burn with financing risk). Technical indicators are broadly neutral with only modest near-term support, valuation offers limited help due to negative earnings and no dividend, while recent financing and strategic reset provide a partial offset.
Positive Factors
Low leverage / modest debt
Modest debt-to-equity (~0.05–0.07) keeps interest burden low and reduces near-term insolvency risk. For a clinical-stage biotech burning cash, low leverage preserves financial flexibility to pursue acquisitions, partnerships, or bridge financing without immediate debt stress.
Negative Factors
No revenue and persistent losses
Absence of commercial revenue and recurring annual losses (~$15–19M) leave the company dependent on clinical progress and external funding. This structural lack of earnings means value creation hinges on successful clinical/regulatory readouts, a high-risk, binary path that can take years.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / modest debt
Modest debt-to-equity (~0.05–0.07) keeps interest burden low and reduces near-term insolvency risk. For a clinical-stage biotech burning cash, low leverage preserves financial flexibility to pursue acquisitions, partnerships, or bridge financing without immediate debt stress.
Read all positive factors
CNS Pharmaceuticals (CNSP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.77M
Dividend YieldN/A
Average Volume (3M)16.54K
Price to Earnings (P/E)―
Beta (1Y)3.77
Revenue GrowthN/A
EPS Growth99.30%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-29.63
Shares Outstanding1,461,449
10 Day Avg. Volume15,052
30 Day Avg. Volume16,543
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit150.62
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$10.00Price Target Upside66.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.67
Revenue Forecast (FY)$40.76M
CNS Pharmaceuticals Business Overview & Revenue Model
Company Description
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthr...
How the Company Makes Money
CNS Pharmaceuticals does not have consistent, disclosed recurring revenue from marketed products; as a clinical-stage company, its operations are primarily funded through financing activities rather than operating income. The company generally rai...
CNS Pharmaceuticals Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -768.00 | 0.00 | -3.31K | -4.13K | -11.76K | -13.07K |
| EBITDA | -16.47M | -15.83M | -14.84M | -18.83M | -15.26M | -14.47M |
| Net Income | -16.49M | -15.85M | -14.86M | -18.85M | -15.27M | -14.50M |
Balance Sheet | ||||||
| Total Assets | 4.65M | 8.62M | 8.70M | 1.70M | 13.05M | 8.76M |
| Cash, Cash Equivalents and Short-Term Investments | 2.95M | 7.20M | 6.46M | 548.72K | 10.06M | 5.00M |
| Total Debt | 232.35K | 328.57K | 326.07K | 300.81K | 409.97K | 387.79K |
| Total Liabilities | 4.58M | 4.10M | 2.52M | 6.13M | 4.92M | 2.14M |
| Stockholders Equity | 70.70K | 4.52M | 6.18M | -4.43M | 8.13M | 6.62M |
Cash Flow | ||||||
| Free Cash Flow | -15.24M | -13.83M | -17.12M | -14.14M | -10.56M | -13.54M |
| Operating Cash Flow | -15.22M | -13.81M | -17.11M | -14.14M | -10.56M | -13.54M |
| Investing Cash Flow | -24.35K | -18.18K | -4.19K | -3.90K | -4.42K | -5.75K |
| Financing Cash Flow | 5.15M | 14.57M | 23.03M | 4.64M | 15.61M | 4.51M |
CNS Pharmaceuticals Technical Analysis
Positive
6.01
Price Trends
5.01
Positive
3.83
Positive
5.40
Negative
Market Momentum
0.13
Negative
56.71
Neutral
89.46
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNSP, the sentiment is Positive. The current price of 6.01 is above the 20-day moving average (MA) of 4.69, above the 50-day MA of 5.01, and above the 200-day MA of 5.40, indicating a neutral trend. The MACD of 0.13 indicates Negative momentum. The RSI at 56.71 is Neutral, neither overbought nor oversold. The STOCH value of 89.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNSP.
CNS Pharmaceuticals Risk Analysis
CNS Pharmaceuticals disclosed 36 risk factors in its most recent earnings report. CNS Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CNS Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $7.77M | -0.18 | -197.11% | ― | ― | 99.30% | |
43 Neutral | $1.17M | >-0.01 | -63.03% | ― | ― | 88.07% | |
| ― | $2.60M | -0.10 | -168.95% | ― | ― | 84.00% | |
54 Neutral | $5.50M | >-0.01 | -82.17% | ― | -34.06% | 79.61% | |
46 Neutral | $3.15M | -0.02 | -199.52% | ― | ― | 97.37% |
* Healthcare Sector Average
CNSP
CNS Pharmaceuticals
5.17
-5.34
-50.81%
BDRX
Biodexa Pharmaceuticals
2.49
-41.21
-94.30%
OGEN
Oragenics
0.59
-0.83
-58.73%
INM
InMed Pharmaceuticals
1.64
-1.11
-40.36%
GRI
GRI Bio
1.74
-44.74
-96.26%
CNS Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
CNS Pharmaceuticals Announces Strategic Oncology-Neurology Realignment
Positive
Jul 2, 2026
On July 2, 2026, CNS Pharmaceuticals posted a June 2026 investor presentation outlining a disciplined strategic reset anchored in oncology and neurology assets. Following a comprehensive review, management concluded that its historic focus on glio...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
CNS Pharmaceuticals Announces Private Placement and Board Changes
Positive
May 4, 2026
On May 4, 2026, CNS Pharmaceuticals entered into a securities purchase agreement with institutional investors for a private placement of 650,000 common shares at $2.30 and pre-funded warrants for 9,143,479 shares at $2.299, for expected gross proc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.